Patents Assigned to GenVec, Inc.
-
Patent number: 9617560Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.Type: GrantFiled: October 5, 2012Date of Patent: April 11, 2017Assignee: GenVec, Inc.Inventors: Douglas E. Brough, Jason G. D. Gall, Duncan McVey
-
Patent number: 9586998Abstract: The invention provides methods for propagating a monkey adenovirus in a cell, including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus, including a replication-deficient monkey adenovirus, obtained by such propagation methods.Type: GrantFiled: August 4, 2015Date of Patent: March 7, 2017Assignee: GenVec, Inc.Inventors: Jason Gall, Douglas Brough, Christoph Kahl, Duncan McVey
-
Patent number: 9580476Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising a nucleic acid sequence encoding one or more Respiratory Syncytial Virus (RSV) antigens and one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein, as well as a method of inducing an immune response against RSV in a mammal by administering the adenovirus or adenoviral vector to the mammal.Type: GrantFiled: October 5, 2012Date of Patent: February 28, 2017Assignee: GenVec, Inc.Inventors: Douglas E. Brough, Jason G. D. Gall, Duncan McVey
-
Publication number: 20160304882Abstract: The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector.Type: ApplicationFiled: June 27, 2016Publication date: October 20, 2016Applicant: GenVec, Inc.Inventors: Jason G.D. Gall, Douglas E. Brough, C. Richter King
-
Patent number: 9388429Abstract: The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector.Type: GrantFiled: May 28, 2014Date of Patent: July 12, 2016Assignee: GenVec, Inc.Inventors: Jason G. D. Gall, Douglas E. Brough, C. Richter King
-
Publication number: 20160122781Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.Type: ApplicationFiled: January 11, 2016Publication date: May 5, 2016Applicant: GenVec, Inc.Inventors: Jason G.D. Gall, Duncan McVey, Douglas E. Brough
-
Publication number: 20160102320Abstract: The invention is directed to a replication-deficient adenoviral vector comprising a nucleic acid sequence encoding a human atonal homolog-1 (Hath1) protein operably linked to a human glial fibrillary acidic protein (GFAP) promoter. The invention also is directed to a composition and method utilizing the adenoviral vector to generate sensory cells in the inner ear of a human.Type: ApplicationFiled: October 9, 2015Publication date: April 14, 2016Applicant: GENVEC, INC.Inventors: Douglas E. Brough, Damodar R. Ettyreddy
-
Patent number: 9233153Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein.Type: GrantFiled: October 5, 2012Date of Patent: January 12, 2016Assignee: GenVec, Inc.Inventors: Jason G. D. Gall, Duncan McVey, Douglas E. Brough
-
Publication number: 20150329834Abstract: The invention provides methods for propagating a monkey adenovirus in a cell, including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus, including a replication-deficient monkey adenovirus, obtained by such propagation methods.Type: ApplicationFiled: August 4, 2015Publication date: November 19, 2015Applicant: GenVec, Inc.Inventors: Jason Gall, Douglas Brough, Christoph Kahl, Duncan McVey
-
Publication number: 20150297699Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.Type: ApplicationFiled: November 12, 2013Publication date: October 22, 2015Applicant: GENVEC, INC.Inventors: Ping Chen, Duncan McVey, Douglas Brough, Joseph Bruder
-
Patent number: 9133248Abstract: The invention provides methods for propagating a monkey adenovirus in a cell including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus. including a replication-deficient monkey adenovirus, obtained by such propagation methods.Type: GrantFiled: November 9, 2010Date of Patent: September 15, 2015Assignee: GenVec, Inc.Inventors: Jason Gall, Douglas Brough, Christoph Kahl, Duncan McVey
-
Patent number: 8920813Abstract: The invention relates to a replication-deficient adenoviral vector comprising two or more nucleic acid sequences encoding Dengue virus antigens and a chimeric hexon protein. The chimeric hexon protein comprises a first portion and a second portion. The first portion comprises at least 10 contiguous amino acid residues from a first adenovirus serotype (e.g., serotype 5 adenovirus hexon protein), optionally with one amino acid substitution. The second portion comprises (a) at least one hypervariable region (HVR) of a hexon protein of an adenovirus of a second adenovirus serotype, or (b) at least one synthetic hypervariable region (HVR) that is not present in the hexon protein of the wild-type adenovirus of the first adenovirus serotype.Type: GrantFiled: December 20, 2011Date of Patent: December 30, 2014Assignee: GenVec, Inc.Inventors: Joseph T. Bruder, Duncan McVey, Douglas E. Brough
-
Publication number: 20140273228Abstract: The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector.Type: ApplicationFiled: May 28, 2014Publication date: September 18, 2014Applicant: GenVec, Inc.Inventors: Jason G.D. Gall, Douglas E. Brough, C. Richter King
-
Patent number: 8765146Abstract: The invention provides adenoviral vectors comprising an adenoviral genome comprising heterologous antigen-encoding nucleic acid sequences, such as Plasmodium nucleic acid sequences, operably linked to promoters. The invention further provides a method of inducing an immune response against malaria in a mammal comprising administering the adenoviral vectors to the mammal.Type: GrantFiled: August 31, 2006Date of Patent: July 1, 2014Assignees: GenVec, Inc., The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The United States of America, as represented by the Secretary of the NavyInventors: Joseph T. Bruder, Imre Kovesdi, C. Richter King, Duncan L. McVey, Damodar R. Ettyreddy, Denise Louise Doolan, Daniel John Carucci
-
Publication number: 20140005257Abstract: The invention is directed to a method of changing the sensory perception of an animal. The method comprises administering an expression vector comprising a nucleic acid sequence encoding an atonal-associated factor, which is expressed to produce the atonal-associated factor resulting in generation of hair cells that allow perception of stimuli in the inner ear. Also provided is a method of generating a hair cell in differentiated sensory epithelia in vivo. The method comprises contacting differentiated sensory epithelial cells with an adenoviral vector (a) deficient in one or more replication-essential gene functions of the E1 region and E4 region, (b) comprising a spacer in the E4 region, and (c) comprising a nucleic acid sequence encoding an atonal-associated factor. The nucleic acid sequence is expressed to produce the atonal-associated factor such that a hair cell is generated. An adenoviral vector encoding an atonal-associated factor also is provided.Type: ApplicationFiled: September 12, 2013Publication date: January 2, 2014Applicant: GENVEC, INC.Inventor: Douglas E. Brough
-
Publication number: 20130337008Abstract: The invention relates to a replication-deficient adenoviral vector comprising two or more nucleic acid sequences encoding Dengue virus antigens and a chimeric hexon protein. The chimeric hexon protein comprises a first portion and a second portion. The first portion comprises at least 10 contiguous amino acid residues from a first adenovirus serotype (e.g., serotype 5 adenovirus hexon protein), optionally with one amino acid substitution. The second portion comprises (a) at least one hypervariable region (HVR) of a hexon protein of an adenovirus of a second adenovirus serotype, or (b) at least one synthetic hypervariable region (HVR) that is not present in the hexon protein of the wild-type adenovirus of the first adenovirus serotype.Type: ApplicationFiled: December 20, 2011Publication date: December 19, 2013Applicant: GENVEC, INC.Inventors: Joseph T. Bruder, Duncan McVey, Douglas E. Brough
-
Patent number: 8454972Abstract: The present disclosure provides compositions for eliciting an immune response, including a prophylactic immune response, against human immunodeficiency virus. The composition includes nucleic acid constructs encoding HIV antigenic polypeptides of multiple clades or strains. Methods for eliciting an immune response by administering the composition to a subject are also provided.Type: GrantFiled: January 20, 2011Date of Patent: June 4, 2013Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, GenVec, Inc.Inventors: Gary J. Nabel, Ling Xu, Bimal Chakrabarti, Lan Wu, Zhi-yong Yang, Jason G. D. Gall, C. Richter King, Zengguang Wang
-
Publication number: 20120316226Abstract: The invention is directed to a method of changing the sensory perception of an animal. The method comprises administering an expression vector comprising a nucleic acid sequence encoding an atonal-associated factor, which is expressed to produce the atonal-associated factor resulting in generation of hair cells that allow perception of stimuli in the inner ear. Also provided is a method of generating a hair cell in differentiated sensory epithelia in vivo. The method comprises contacting differentiated sensory epithelial cells with an adenoviral vector (a) deficient in one or more replication-essential gene functions of the E1 region and E4 region, (b) comprising a spacer in the E4 region, and (c) comprising a nucleic acid sequence encoding an atonal-associated factor. The nucleic acid sequence is expressed to produce the atonal-associated factor such that a hair cell is generated. An adenoviral vector encoding an atonal-associated factor also is provided.Type: ApplicationFiled: June 26, 2012Publication date: December 13, 2012Applicant: GENVEC, INC.Inventor: Douglas E. Brough
-
Patent number: 8323663Abstract: The invention is directed to an adenoviral vector comprising at least one nucleic acid sequence encoding an aphthovirus antigen and/or a cytokine operably linked to a promoter. The adenoviral vector is replication-deficient and requires at most complementation of both the E1 region and the E4 region of the adenoviral genome for propagation. The invention also is directed to a method of inducing an immune response in a mammal comprising administering to the mammal a composition comprising the aforementioned adenoviral vector.Type: GrantFiled: May 8, 2008Date of Patent: December 4, 2012Assignee: GenVec, Inc.Inventors: Douglas E. Brough, Joseph T. Bruder, C. Richter King, Marvin J. Grubman, John G. Neilan
-
Publication number: 20120302627Abstract: The invention provides a method of inducing an immune response against a human immunodeficiency virus (HIV) in a mammal. The method comprises administering to the mammal an adenoviral vector composition comprising one or more adenoviral vectors encoding two or more different HIV antigens, the production of which induces an immune response against HIV in the mammal. The invention also provides an adenoviral vector composition comprising four adenoviral vectors encoding an HIV clade A Env protein, an HIV clade B Env protein, an HIV clade C Env protein, and a fusion protein comprising an HIV clade B Gag protein and Pol protein, respectively.Type: ApplicationFiled: August 7, 2012Publication date: November 29, 2012Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, GENVEC, INC.Inventors: Gary J. Nabel, Cheng Cheng, Wing-Pui Kong, Jason G.D. Gall, C. Richter King